The use of levodopa for treatment of Parkinson's disease is a well-established clinical practice. Data about the true incidence and severity of cutaneous complications associated with the use of levodopa are largely lacking. Aim of this review was to evaluate the quality of evidence referring to the skin disorders caused by levodopa treatment for Parkinson's disease. Thirty of 1084 studies were included; 8 randomized controlled trials and 22 case reports in a total of 2749 patients. Malignant melanoma was the most frequent oral levodopa-related skin disorder followed by allergic cutaneous reactions, alopecia, vitiligo, skin hyperpigmentation, Laugier-Hunziker syndrome, Henoch-Schönlein syndrome, pseudobullous morphea and scleroderma-like illness. Naranjo scores ranged from 2 to 8. Regarding levodopa clinical trials, the most frequent skin complication was peripheral edema, followed by malignant melanoma. Although evidence is not robust, melanoma is the most frequent and possible fatal levodopa-associated skin disorder, while other skin allergic or immunological reactions are less common and reversible. Although levodopa treatment may induce melanogenesis and promote melanomagenesis, existing evidence does not support an association between levodopa therapy and induction or progression of malignant melanoma. The suggested association with melanoma may reflect the well-documented association of Parkinson's disease with melanoma rather than the exposure to the drug. Nevertheless, until a solid conclusion can be drawn, the use of levodopa in the context of malignant melanoma should be considered with caution. Well-designed prospective studies are needed to determine the cause and effect relationship between levodopa and skin disorders.
Introduction
Nowadays, in the field of movement disorders, extensive research tends to focus on non-neuronal peripheral tissues, such as skin, as key to the pathogenesis of Parkinson's disease (PD) [1] . Recent evidence suggests that α-synuclein (α-Syn), the histopathological hallmark of PD-pathology may begin in the skin and colon before spreading to the olfactory bulb and caudal brainstem, although others suggest that skin nerve fibers are secondarily affected following the spread of α-Syn to the periphery [2] .This temporal sequence may explain the manifestation of non-motor skin disorders, such as seborrheic dermatitis (range 52-59%), rosacea (7.62%) and bullous pemphigoid (range 3-26%) before the first motor signs of PD [3] [4] [5] . Therefore, they may be early indicators of PD and clinicians should be aware of this fact in their daily practice. Studies have also shown an up to fourfold increased risk of malignant melanoma (MM) and non-melanoma skin cancers in PD patients [6] [7] [8] [9] . The causal relationship and the exact molecular mechanisms remain unclear; however, suggested common pathways include mitochondrial dysfunction, altered melanin/neuromelanin production, impaired tyrosine metabolism, 129-ser phosphorylated-α-Syn deposits and genetic intersections [6, 7] .
Levodopa (l-dopa), derived from seedling of Viciafaba beans, is the natural l-isomer of the amino acid d, l-dihydroxyphenylalanine. In 1960, Ehringer and Hornykiewicz discovered dopaminergic deficiency in patients with PD [10] . In 1970, the US Food and Drug Administration approved the use of oral l-dopa in PD. Levodopa-carbidopa intestinal gel (LCIG) has been administered since 2004 by continuous intra-intestinal infusion (duodopa ® ) to provide relatively stable plasma l-dopa levels. l-dopa remains the gold standard for PD motor symptoms, and is considered as one of the greatest breakthroughs of modern neuroscience [1] .
Skin symptoms may occur as adverse events (AEs) of the classical l-dopa therapy (including decarboxylase inhibitors such as carbidopa). However, these associations are poorly understood, and have not been described in detail yet in neurological textbooks or published articles [11] . Previous reviews focused only on associations between skin MM and l-dopa, perhaps due to the high mortality rate [8] [9] [10] [11] [12] . Data about the true incidence and severity of the skin complications due to l-dopa are largely lacking. The purpose of this review is to identify reports assessing the relationship between l-dopa and skin disorders, and to critically evaluate all clinical studies concerning l-dopa-induced skin disorders.
Materials and methods
This is a systematic literature search, based on the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [13] . Given the rarity of these drug reactions, we searched for interventional and observational studies (case-control, cross-sectional and cohort studies) between 1st January 1970 and 1st March 2018. We searched electronically from 1970 to March 2018 the following databases: MEDLINE, Google Scholar, Scopus, and the Food and Drug Administration (FDA) Web site with key search words: "oral l-dopa", "decarboxylase inhibitors", "carbidopa", "levodopa carbidopa intestinal gel", "duodopa ® ", immediate-release oral levodopa-carbidopa'', "extended-release carbidopa-levodopa", "inhaled levodopa", "skin disorders", "dermatological manifestations", "skin lesions", "Parkinson disease." The reference list of each article was searched manually for any additional pertinent citations, so that significant papers should not be missed. The inclusion criteria were: (1) a clinical diagnosis of PD, (2) a temporal relationship between l-dopa alone or combined with decarboxylase inhibitors and skin disorder in patients with PD. Exclusion criteria were: (1) articles not published in English, (2) reviews, letters, summaries, dissertations, theses, (3) studies that used children or animal models and (4) studies that reported data not related to l-dopa skin complications in patients with PD.
Study selection and data extraction
Two investigators (named AB, NS) with advanced training in antiparkinsonian pharmacotherapy and critical appraisal screened all titles and abstracts retrieved through the search. We further examined all full-text articles of identified abstracts that met inclusion criteria. In case of debate during the eligibility assessment, the third study investigator (named LS) reviewed the abstract/full text in doubt and made a final objective approval. After retrieving the full text of included studies, the three investigators (AB, NS, LS) independently assessed the methodological quality of randomized controlled trials (RCTs) studies according to Cochrane Handbook for systematic Reviews of Interventions [14] , and the Naranjo adverse drug reaction probability scale for assessing the quality of case reports [15] .
The variables extracted from each manuscript were the following: study characteristics (including design), characteristics of patients (age, gender), l-dopa and other dopaminergic therapies, time of symptoms appearance after l-dopa therapy onset and type of cutaneous AEs. For case reports, each author rated each case independently, using the Naranjo adverse drug reaction probability scale [15] . The adverse drug reaction is assigned to a probability category on the basis of the total score as 'definite' = ‡9, 'likely' = 5-8, 'possible' = 1-4, 'doubtful = 0 or less. When scoring was discrepant, a reconciliation process was completed that involved each author reviewing both scores of each discrepant case, and then discussing the case to reach a consensus score. Authors kept original score, if it was calculated by the article, without performing their own rating. An academic dermatologist (AK) has improved the dermatological aspects of this review.
Results
From a total of 1084 identified articles, 911 were excluded after title and abstract screening, as they were not related to the subject, 142 were excluded after full-text screening as not fulfilling the inclusion criteria, e.g., not English language, animal studies, reviews, not confirming relationship between l-dopa and skin disorder (Fig. 1) . No further relevant citations were found from weekly electronic database updates up to June 1, 2018. Finally, we analyzed 30 articles, 8RCT and 22 case reports with a total of 2.749 PD patients (Tables 1, 2 ). Given the heterogeneity of studies, it was impossible to conduct meta-analysis. Thus, we provide a narrative summary of results, as follows:
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Observational studies (case reports)
The majority of observational studies yielded by our research regarded case reports (22 articles involving a total of 32 patients) . The most frequent skin disorder reported was skin melanoma (13/32: 40.62%) followed by allergic cutaneous reactions (8/32: 25%), vitiligo (1/32: 3.1%), alopecia (2/32: 6.25%), skin hyperpigmentation (4/32: 12.5%), Laugier-Hunziker-like syndrome (1/32: 3.1%), Henoch-Schönlein syndrome (1/32: 3.1%), pseudobullous morphea and scleroderma-like illness (1/32: 3.1%), and eosinophilic fasciitis (1/32: 3.1%).
Robinson et al. [16] reported the case of a 50-year-old man who was diagnosed with malignant melanoma 21 days after receiving a trial course of l-dopa 100 mg/d. Lieberman and Shupack described two male PD patients, aged 70 years and 62 years, who were diagnosed with cutaneous melanoma after starting l-dopa treatment [17] . l-dopa was discontinued in the former patient, with a comment that PD became noticeably worse after the introduction of l-dopa, while the latter patient died from increased intracranial pressure 2 months after starting l-dopa, although, there was no autopsy confirmation of a metastatic process. Sober and Wick [18] in their prospective study of 1099 cutaneous MM patients found only one patient who was on l-dopa. Bernstein et al. [19] reported a 74-year-old woman in whom three distinct primary melanomas developed after she had been receiving long-term therapy with l-dopa. Kochar et al. [20] reported a 59-year-old woman with PD who developed metastatic MM four months after the initiation of l-dopa. Rampen et al. [21] reported three PD patients showing temporal association between l-dopa therapy and development of MM. Although l-dopa was continued, no recurrence was recorded in two of the patients, while the third remained also free of disease after discontinuation of l-dopa. Haider and Thaller [22] reported a 73-year-old woman with PD who In the first patient, l-dopa was continued because of severe PD motor symptoms, but treatment was discontinued in the second patient due to the mild nature of PD.
Neither of them showed signs of metastatic disease. Charles et al. [24] reported a 58-year-old man who developed 22 MM after starting l-dopa. The MMs were attributed to the presence of specific mutations (i.e., CDKN2A, CDK4 and MC1R) that had been associated with a high risk for cutaneous MMs. Of note, in all the aforementioned reports, there was no information about environmental factors (i.e., UV radiation) or other risk factors that might be pathogenetically related.
As concerns (pseudo)-allergic cutaneous reactions caused by l-dopa treatment, very few cases of skin rashes have been reported following the use of carbidopa/levodopa (Sinemet ® 25/100) with yellow dye. Goetz reported five patients with maculo-papular rashes on the trunk and arms, which resolved following discontinuation of carbidopa/levodopa 25/100 over 3-6 weeks [25] . Chou et al. [26] reported two patients under carbidopa/levodopa 25/100 treatment, both of whom developed a skin rash which reoccurred when the drug was reintroduced. Cansino-Torres et al. [27] reported a 77-year-old woman with PD who developed drowsiness, heartburn, excessive sweating, bilateral tearing, conjunctival injection, and rhinorrhea immediately after the first dose of carbidopa/levodopa (Sinemet ® 25/100). She became hypertensive and tachycardic. Within 3 h of this dose, a pruritic rash appeared involving mainly her face, neck, and chest [27] .
Immune-related AEs to l-dopa are infrequent. Niedermaier et al. [28] reported Sinemet (carbidopa 25 mg/levodopa 250 mg) induced Henoch-Schönlein syndrome in a 68-year-old man with PD and vasculitis. When Sinemet was replaced by Madopar (l-dopa 100 mg/benserazide 25 mg) four times daily, the symptoms disappeared. Esteban-Fernandez et al. [29] reported an extremely rare case of carbidopa-induced eosinophilic fasciitis (EF), an immune-mediated disorder of unclear aetiopathogenesis. A 76-year-old male with PD, treated with l-dopa/carbidopa 100/25 mg tid, developed a painful, progressive increase in waist circumference over 6 weeks along with swelling of all four limbs, with significant deterioration when the dose of l-dopa/carbidopa was increased. The diagnosis of eosinophilic fasciitis (EF) was histologically confirmed. After withdrawing l-dopa/carbidopa, the patient remained asymptomatic during the follow-up period. Joly et al. [30] reported a case of scleroderma-like illness, manifested by pseudobullous morphea and eosinophilia, in a 79-year-old man under treatment with l-5-hydroxytryptophan and carbidopa for PD and chronic depression. Two years after starting treatment with tryptophan, the patient complained of pruritus and a burning sensation in his skin. Clinical examination revealed mild edema of the forearms, chest and legs, but no sclerodactyly or telangiectases. Most importantly morphealike plaques with flaccid pseudo-bullous lesions were noted on the legs. There was marked eosinophilia and positive antinuclear antibodies (1:250). Histology showed massive superficial edema and scleroderma-like changes. Within the first month of l-5-hydroxytryptophan discontinuation and prednisone initiation, skin tightness and tenderness resolved considerably. A significant association between the ingestion of tryptophan and eosinophilia-myalgia syndrome, has been established. In addition, there were three cases, including this case, of tryptophan-induced scleroderma-like syndromes. According to the authors, drugs like carbidopa, which produces changes in tryptophan metabolism, may be associated with the development of fibrosing syndromes in persons with underlying host susceptibility. This case suggests that a confluence of genetic and environmental cofactors may be involved.
To date, five cases of l-dopa -induced hyper-or-hypopigmentation disorders have been reported. Grainger reported a 51-year-old man with darkening of his white beard 8 months after starting l-dopa [31] . Similarly, Reynolds et al. [32] described a patient with PD who noted that his white hair turned gray and darkened 8 months after the addition of carbidopa to his established l-dopa therapy and 4 months after the introduction of bromocriptine. Komagamine et al. [33] reported a 74-year-old man with PD who noticed darkening of his white hair ten months after administration of l-dopa. Munhoz et al. [34] also reported an 85-year-old PD patient who showed darkening of his white hair that began following the introduction of Mucuna pruriens extract (MPE) at a dose equivalent to 1000 mg of l-dopa/day. Vega Gutiérrez et al. [35] presented a typical picture of Laugier-Hunziker syndrome including brown hyperpigmented macules on the lips, nails, oral and genital mucosa in a 72-year-old female with PD, 1 year after starting treatment with l-dopa. Two years after the first lesions occurred, the patient complained of tiredness, weight loss (6-8 kg), and abdominal symptoms. She was diagnosed with Addison's disease. Hormonal replacement therapy with hydrocortisone and fludrocortisone succeeded in controlling clinical and laboratory manifestations and reducing considerably the degree of mucocutaneous hyperpigmentation. However, initial hyperpigmented macules persisted.
A 50-year-old white man with PD developed achromic lesions of both forearms 1 week after l-dopa/carbidopa 375 and 37.5 mg/day and tolcapone 300 mg/day. The diagnosis of these lesions was vitiligo. Due to severity of his motor symptoms, patient continued l-dopa. In the following months, his skin lesions continued to enlarge and reached the elbow, and new achromic lesions appeared on both knees [36] .
There are scarce reports of alopecia induced by l-dopa among patients with PD. In a 54-year-old woman with PD, severe diffuse alopecia occurred 3 months after first taking l-dopa. Another patient was a 63-year-old woman with a 20-year history of PD who also had diffuse alopecia. Although it was explained to them that their hair loss might be associated with l-dopa, they preferred to continue treatment, and partial alopecia persisted [37] .
l-dopa clinical trials
In CALM-PD Study, three hundred and one patients were randomly assigned to receive pramipexole (n = 151) or carbidopa/levodopa (n = 150). Significantly, fewer patients in l-dopa group experienced both generalized n = 12 and peripheral edema n = 6 compared to pramipexole group (27 and 22, respectively) [38] . No other significant skin reactions were noted.
Stocchi et al. [39] in a prospective, long-term (4-year) trial studied forty patients randomized to receive either subcutaneous infusion of the dopamine agonist lisuride (n = 20) or conventional therapy with oral levodopa and dopamine agonists (n = 20). Four patients (from oral levodopa group) reported peripheral edema as mild AE.
Fahn et al. [40] evaluated 361 patients with early Parkinson's disease who were randomized to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or 150 and 600 mg, respectively, or a matching placebo for a period of 40 weeks. MM was recorded in two patients who both received l-dopa at 150 mg and 600 mg: one patient in placebo group and one patient received 600 mg of l-dopa. In the patient who received 600 mg of l-dopa, melanoma was recorded after the end of the study.
Rascol et al. [41] evaluated 687 outpatients who were randomized to receive oral rasagiline (231 individuals; 1 mg once daily), entacapone (n = 227; 200 mg with every l-dopa dose), or placebo (n = 229). Peripheral edema was reported in all groups, but it resolved in one week [41] .
In the Blindauer et al. study, three hundred and twentyseven patients were randomized to receive either etilevodopa-carbidopa or levodopa-carbidopa for 18 weeks. Only peripheral edema was significantly more frequent in the etilevodopa-carbidopa group compared to the levodopa-carbidopa group (P = .003); however, when mild events were excluded, this difference was no longer significant [42] .
Three hundred and ninety-three patients were randomly allocated to 13 weeks of double-blind treatment with extended-release (n = 201) or immediate-release carbidopa-levodopa (n = 192) plus matched placebos. Eight patients (4 from each group) reported peripheral edema as AE [43] .
In a 12-week double-blind, double dummy study, seventyone patients in the safety analysis had a percutaneous endoscopic gastrojejunostomy (PEG-J) placed before receiving either LCIG infusion and oral placebo capsules or placebo gel infusion and encapsulated immediate-release oral levodopa-carbidopa (IR-LC) tablets; Skin erythema was the most frequent related to device in 7/37 of LCIG patients versus 4/34 of oral CL patients (Table 2) . It was of mild severity and resolved in one week after stopping the treatment [44] .
Five hundred and ninety-nine patients (safety set) were randomly assigned to oral treatment with opicapone (5 mg, 25 mg, or 50 mg once daily), placebo, or entacapone (200 mg with every l-dopa intake) plus levodopa-carbidopa for 14-15 weeks. MM was reported as serious AE in one patient from the placebo group receiving only levodopa-carbidopa [45] .
Assessment of risk of bias and quality of included clinical trials
Three of the authors (AB, NS LS) independently appraised the methodological quality of the included trials using the Cochrane risk of bias tool for RCTs, which incorporates sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias (Table 3) . Each item is rated as "yes", "no", or "unclear". The quality of clinical trials can be divided into three levels. If the study design satisfied all the preceding six criteria, it is considered A level, which means a low risk of bias. B level is assigned if one or more criteria are partly met, and when one or more criteria are not met, the study was defined as C level, implying high risk of bias. Our review identified eight RCTs with moderate methodological quality of level B.
Discussion
In this review of skin disorders induced by l-dopa therapy among patients with PD, the most frequently reported cutaneous association was MM. Eight RCTs of moderate methodological quality had been reviewed, none of which showed any significant association. Nevertheless, no robust evidence can be produced due to the small number of trials and other methodological considerations. In the present review, we included only studies with a strict temporal relationship between l-dopa therapy and development of MM in patients with PD. In contrast, previous reviews did not exclude patients with a history of MM before starting l-dopa therapy for PD [46] . We also sought to evaluate studies designed to examine the relationship between l-dopa and MM, excluding other cancers or medical conditions; whereas in the DATATOP (Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism) trial, MM was mostly assessed along with other skin malignancies [47] .
Epidemiological studies have clearly shown that MM occurs more frequently among patients with PD and vice versa [48, 49] . This positive association may be explained by common pigmentation changes in melanin and/or melanin synthesis enzymes, genetic correlations, and deficits in cellular processes, such as autophagy or protein homeostasis [12] . Although some studies suggested that l-dopa may increase the risk of developing MM, this issue remains controversial [49] . l-dopa is a product of tyrosine through tyrosine hydroxylase (TH), a key enzyme also for the production of melanin, but also abundantly present in ΜΜ tumor cells. Exogenous l-dopa may also increase melanogenesis and possibly promote MM growth [50] . Overexpression of TH might also be toxic because of increased melanin precursors, such as DOPA and dopaquinone, and could also facilitate tumor growth of melanin-producing cells [48, 50] . Scarce reports of patients who developed ΜΜ after starting l-dopa therapy for PD, suggested that l-dopa should not be used in patients with history of MM [19] . There is an inherent paradox in the association of PD with MM, in the sense that PD is a disease of loss of melanin-containing neurons, but is associated with enhanced growth of melanin-producing skin cells. Theoretically, this paradox could be resolved if the established association between PD and MM was due to the administration of l-dopa, which could, as mentioned, lead to enhanced possibility of aberrant growth of melaninproducing skin cells, while at the same time providing symptomatic benefit to patients.
More systematic analysis of reports, however, has led to the conclusion that it is unlikely that there is an association between l-dopa therapy and induction or progression of MM [47] . The largest recent meta-analysis of 24 studies confirmed an association between PD and MM, stating that: "it is PD that increases the risk of MM rather than l-dopa therapy" [12] . However, this meta-analysis included only two small observational studies evaluating the association between melanoma and l-dopa therapy. Olsen et al. [51] concluded that the increased rate of MM observed in patients treated at hospital for PD was restricted to those with idiopathic PD, regardless of treatment with l-dopa. DATATOP (1985-1987) was a placebo-controlled clinical trial designed from 1985 to 1987 to test the hypothesis that long-term treatment of patients with early PD with deprenyl 10 mg/day and/or tocopherol (vitamin E) 2000 IU/day would extend the time until disability requires therapy with l-dopa. Constantinescu et al in the DATATOP trial found that the incidence of MM was higher than expected in this PD cohort. In contrast, rates of MM before and after initiation of l-dopa were similar. Moreover, the time delay between initiation of l-dopa therapy and the diagnosis of melanoma was in two of the three cases very short. Both of these facts argue against a causal relationship between l-dopa therapy and MM. However, according to the authors, the DATATOP study was not designed, nor powered for assessing such a relationship [47] . Lastly, these studies did not collect sufficient data on risk factors (environmental toxins; pigmentation related genes, such as MC1R, CYP2D6 or GSTM1; vitamin D receptors; alterations or mutations in parkin, alpha-synuclein, LRRK2, DJ-1, or other PD-related genes) to explore potential explanations. Collectively, these large studies suggest that there is a weak, if any, causal link between l-dopa-therapy and MM development and progression [12, [47] [48] [49] . It is unclear whether there is a direct effect of l-dopa on MM, or whether the association reflects PD rather than exposure to the drug.
Among the most interesting points of our review is the emergence of other rare skin manifestations, such as carbidopa-induced scleroderma-like disorder spectrum, including EF. The suspected mechanism is an increased bioavailability of 5-hydroxytryptophan, which is thought to be responsible for the sclerodermiform symptomatology, as proven with its exogenous administration. Although the exact mechanism remains obscure, an abnormal immune response triggered by l-dopa may be involved. Regarding EF, increased [31] . This association was based on the evolution of clinical symptoms, the cutaneous manifestations, the response to treatment, and the particular clinico-histopathological characteristics of Laugier-Hunziker syndrome. Although many questions remain unanswered regarding this association, melanocytic hyperactivity is undoubtedly the common ground among these conditions. Moreover, a synergistic effect of levodopa on the melanocyte dysfunction in susceptible individuals cannot be excluded.
Another important, albeit less studied, is hair loss induced by l-dopa. In a previous review, the majority of reports suggested dopamine agonist to be responsible; only one report described two patients developing hair loss under l-dopa therapy [52] . There is evidence that sympathetic nerve fibers are involved in hair growth control. Nevertheless, the actual pathophysiological relationships between dopaminergic drugs and hair loss remain unclear [53] . There is also evidence for prolactin's role in hair follicle cycling. Treatment of hyperprolactinemia with bromocriptine, a dopamine agonist that inhibits prolactin, can result in alopecia [54] . Further research into neuro-hormonal regulation of the hair follicle cycle may help to elucidate the pathophysiology of dopamine-associated telogen effluvium. In addition, the reason why female patients are more commonly affected compared to males, although data are poor [52] , in above studies also remains uncertain. It is well known that telogen effluvium is far more common in women than in men. It is possible that hormonal influences of dopamine may contribute along with other factors, such as iron deficiency and thyroid dysfunction.
Although drug-induced allergic cutaneous reactions are considered common, only two reports have been published regarding carbidopa/dopa (Sinemet ® 25/100)-induced maculopapular rash without vasculitis. The yellow dye used in this specific preparation was suspected to be responsible, as no more cases have been reported since using tablets with blue dye. Previous large multicenter randomized controlled trials showed that treatment with l-dopa alone did not cause skin rash. It seems that the incidence of skin allergy to Sinemet ® 25/100 is extremely low; true l-dopa skin allergy may be non-existent in practice. However, practitioners should be vigilant for mild allergic reactions. This is particularly important because Sinemet-induced vasculitis and glomerulonephritis have already been reported [28] . The most common mechanism involved was a type III hypersensitivity reaction mediated by the deposition of antigen-antibody complexes in small vessel walls and in the glomeruli. In animal studies, Sinemet augments the content of dopamine in the brain and thus modulates immune responses [55] . However, it is unclear whether a mild allergic [56] response causes skin lesions without clinical evidence of systemic disease and more severe reactions cause clinically overt systemic disease such as glomerulonephritis.
This review summarized data on the largest and longest clinical trials of l-dopa regarding skin-related disorders in PD patients. The selected studies included 2717 patients all of whom had an average exposure that exceeded 2 years (Table 2 ). All skin-induced complications appeared within the first 28 days of treatment. In Table 2 , peripheral edema was the most common l-dopa skin-related disorder (5/8 studies), followed by melanoma (2/8 studies), basal cell carcinoma (1/8 studies) and erythema (1/8 studies). There was no detailed description of the type of skin lesion and no comparison was made with the expected prevalence of skin problems in the reference population. Peripheral edema is most frequently seen as a side effect of dopamine agonists (e.g.. pramipexole) than l-dopa, but the exact pathogenetic mechanism is unknown [57] . Dopamine is considered as an important regulator of the sympathetic nervous system, aldosterone secretion, and ATP-mediated sodium and potassium channels and thus can produce peripheral side effects. Ηοwever, predisposing factors and premorbid conditions (e.g. cardiac failure) were not considered in aforementioned studies. On the other hand, none of these studies was designed, nor powered for assessing a causal relationship between melanoma and l-dopa. Interestingly, Fahn et al. [40] reported only two cases of melanoma: one patient in placebo group and one patient received 600 mg of l-dopa, while Ferreira et al. [45] reported one patient in placebo, suggesting of a random event. An independent adjudication committee (comprised of three board-certified gastroenterologists, each with > 25 years of experience in the placement and management of PEG and J-tubes) assessed the safety rates and concluded that there were no series of events or sentinel event(s) that should limit use of the device in the advanced PD patient population. Future studies are necessary to gather more long-term data on the safety and efficacy of drug delivery via percutaneous endoscopic gastrojejunostomy, and perhaps on mechanisms of l-dopa skin-related disorders [58] .
Nonetheless, several limitations were identified in the included studies which compromised their external validity. Considering the heterogeneity of study designs and outcome measures of included studies, it was not possible to conduct statistical pooling of the results. Most studies regarded case reports; hence, the quality of the evidence was not robust (our Naranjo score ranged from 2 to 8, which denotes a moderate quality). There was considerable heterogeneity among published reports, likely due to differences in the exclusion criteria of other potential causes of skin lesions [17] and lack of specific biomarkers [16, 17, 19, [30] [31] [32] [33] [34] . Indeed, in some cases, the work-up was incomplete [17, 19, 23, 24, 27, 29, 34, 35] . The data from these case reports are also limited in terms of patient characteristics that could be correlated with environmental risk factors for melanoma, such as sun exposure, family history, or fair skin. In only one case without a family history, 22 melanomas were attributed to specific mutations [33] .There was a lack of clinical information such as recurrence of symptoms after l-dopa discontinuation [17, 25, 26, [29] [30] [31] 35] or after l-dopa re-administration [17, 19, 23, 25, 26, 30, 31, [34] [35] [36] . Although well-designed studies including randomized controlled trials could contribute data on the skin AEs of l-dopa, such trials are largely lacking. Skin AEs of l-dopa originate from the FDA Adverse Event Reporting System and case reports. However, the FDA Adverse Event Reporting System cannot be used to determine the incidence of AEs, as they are under-reported and neither patient exposure nor the amount of time the drug was in the market is taken into consideration.
Limitations
This review is not without limitations. First, skin disorders associated with l-dopa are rare; thus, only a small number of studies were available for analysis. Second, we searched a limited number of databases. Consequently, there is always the possibility that we overlooked studies in other databases published before 1970. In addition, there is always the possibility of publication bias due to underreported negative results. However, the use of fewer search limits increases the sensitivity of the database search method, thus, we believe that the current search is extensive and includes all available literature.
Conclusions
Despite the aforementioned limitations, this review provides a foundation for further research on the incidence of cutaneous AE of l-dopa therapy for PD. A causal relationship between l-dopa and the described skin disorders cannot be supported by the existing limited data. None of the reviewed studies was adequately organized to investigate the possible causal relationship between l-dopa and skin disorders. Regarding cutaneous MM, in most case reports as well as in some clinical trials, there was only a temporal relationship between the onset of l-dopa therapy and the development of MM. On the other hand, some of the skin disorders like hair loss or vitiligo are very rare AEs, and a true association cannot be documented. In this review, the published studies (mainly cases reports) lack homogeneous populations and specific biomarkers. MΜ is the most frequent and possible fatal l-dopa-associated skin disorder, while most other skin allergic or immunological reactions are less common and reversible. Although l-dopa treatment may induce melanogenesis and promote melanomagenesis, existing evidence does not support an association between l-dopa therapy and induction or progression of ΜΜ. The suggested association with ΜΜ may reflect the well-documented association of PD with ΜΜ rather than the exposure to the drug. Nevertheless, until a solid conclusion can be drawn, the use of l-dopa in the context of ΜΜ should be considered with caution. Well-designed prospective studies are necessary to assess cause-effect relationship between l-dopa and skin disorders. Further research should also focus on comprehension of risk factors for l-dopa-associated skin disorders.
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